Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

Clinical trial NCT06278870 · RECRUITING

Trial details

NCT number: NCT06278870
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

HER2-positive Metastatic Breast Cancer First-line Treatment

Start date: 2023-09-06
Primary completion: 2031-06-30
Enrollment: 312

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.